Arvinas PROTAC protein degraders have some potential, with vepdegestrant as its late-stage, most promising asset, partnered ...

This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return ...

Arvinas Inc. (NASDAQ:ARVN) is one of the best low priced pharma stocks to buy now. Earlier on June 13, Arvinas presented ...

– John Houston, Ph.D., Chairperson, CEO and President at Arvinas, Announces Plans to Retire as CEO Upon Appointment of Successor – – Dr. Houston to Remain Chairperson of Arvinas Board of ...

SmallCap stocks can often be overlooked by institutional investors, yet they offer outsized return potential for those ...

During his tenure as CEO, Dr. Houston has been instrumental in Arvinas’ success moving six programs into the clinic, reporting the results of the first positive pivotal Phase 3 trial for a PROTAC, and ...

Arvinas on Wednesday said Houston, who has been president and chief executive of the New Haven, Conn., company since September 2017, will retire from those positions upon the appointment of a ...

Alkermes ALKS announced positive top-line data from the phase II Vibrance-1 study, which evaluated its novel, investigational ...

Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements.

It might be prudent to make a point of collecting a little more cash in the near future, and worry a little less about growth ...